文献速递脑血管病

觉醒型卒中与非觉醒型不明发病时间卒中的溶栓治疗:EOS个体患者数据Meta分析

Thrombolysis for Wake-Up Stroke Versus Non-Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis.
PubMed 文献 · Stroke · 2024-03-08

基于两项随机对照试验的个体患者数据,比较觉醒型卒中(WUS)与非觉醒型不明发病时间卒中(non-WUS)静脉溶栓的疗效与安全性。共纳入634例患者,其中542例WUS、92例non-WUS。发病方式与治疗效应间无显著交互作用(交互P=0.796);WUS患者溶栓组90天良好预后显著优于对照组(54.8% vs 45.5%,校正OR 1.47,95%CI 1.01-2.16),non-WUS组差异无统计学显著(37.2% vs 29.2%,校正OR 1.76,95%CI 0.58-5.37)。

要点

  • WUS与非WUS患者静脉溶栓疗效间无显著交互作用(交互P=0.796)。
  • WUS患者溶栓组90天良好预后54.8% vs 对照组45.5%(校正OR 1.47,95%CI 1.01-2.16)。
  • non-WUS患者良好预后37.2% vs 29.2%(校正OR 1.76,95%CI 0.58-5.37),统计效能不足。

核心结论

  • 静脉溶栓对WUS与non-WUS患者的效应无差异。
  • 静脉溶栓在WUS患者中显示显著获益,而在non-WUS亚组中统计效能不足以检出实质性获益。

研究设计与样本

  • 基于EOS数据集中的WAKE-UP与THAWS两项随机对照试验的个体患者水平数据,比较静脉溶栓与安慰剂或标准治疗。
  • 共分析634例不明发病时间卒中患者,其中WUS 542例(女性191例,接受阿替普酶272例),non-WUS 92例(女性42例,接受阿替普酶43例)。
  • 预设良好结局为90天改良Rankin量表评分0至1分。
  • 安全性结局包括22至36小时症状性颅内出血和90天死亡。
  • 采用多变量logistic回归分析比较WUS与non-WUS两组治疗效应。

主要发现

  • 发病方式与治疗效应间无显著交互作用(交互P=0.796)。
  • WUS患者中,溶栓组与对照组良好预后频率分别为54.8%与45.5%(校正OR 1.47,95%CI 1.01-2.16)。
  • WUS患者中,溶栓组与对照组死亡分别为4.0%与1.9%(P=0.162),症状性颅内出血分别为1.8%与0.3%(P=0.194)。
  • non-WUS患者中,溶栓组与对照组良好预后分别为37.2%与29.2%(校正OR 1.76,95%CI 0.58-5.37),无显著差异。
  • non-WUS患者中,溶栓组报告1例死亡和1例症状性颅内出血,对照组均无。

局限性

  • non-WUS亚组统计效能不足以检出实质性获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stroke with unknown time of onset can be categorized into 2 groups; wake-up stroke (WUS) and unwitnessed stroke with an onset time unavailable for reasons other than wake-up (non-wake-up unwitnessed stroke, non-WUS). We aimed to assess potential differences in the efficacy and safety of intravenous thrombolysis (IVT) between these subgroups. METHODS: Patients with an unknown-onset stroke were evaluated using individual patient-level data of 2 randomized controlled trials (WAKE-UP [Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke], THAWS [Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes With Alteplase at 0.6 mg/kg]) comparing IVT with placebo or standard treatment from the EOS (Evaluation of Unknown-Onset Stroke Thrombolysis trial) data set. A favorable outcome was prespecified as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage at 22 to 36 hours and 90-day mortality. The IVT effect was compared between the treatment groups in the WUS and non-WUS with multivariable logistic regression analysis. RESULTS: Six hundred thirty-four patients from 2 trials were analyzed; 542 had WUS (191 women, 272 receiving alteplase), and 92 had non-WUS (42 women, 43 receiving alteplase). Overall, no significant interaction was noted between the mode of onset and treatment effect (P value for interaction=0.796). In patients with WUS, the frequencies of favorable outcomes were 54.8% and 45.5% in the IVT and control groups, respectively (adjusted odds ratio, 1.47 [95% CI, 1.01-2.16]). Death occurred in 4.0% and 1.9%, respectively (P=0.162), and symptomatic intracranial hemorrhage in 1.8% and 0.3%, respectively (P=0.194). In patients with non-WUS, no significant difference was observed in favorable outcomes relative to the control (37.2% versus 29.2%; adjusted odds ratio, 1.76 [0.58-5.37]). One death and one symptomatic intracranial hemorrhage were reported in the IVT group, but none in the control. CONCLUSIONS: There was no difference in the effect of IVT between patients with WUS and non-WUS. IVT showed a significant benefit in patients with WUS, while there was insufficient statistical power to detect a substantial benefit in the non-WUS subgroup. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: CRD42020166903.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kamogawa N, Miwa K, Toyoda K, et al. Thrombolysis for Wake-Up Stroke Versus Non-Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis. Stroke. 2024. PMID: 38456303. doi:10.1161/STROKEAHA.123.043358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。